Conclusions: Icaritin has demonstrated satisfactory clinical safety and immunomodulatory clinical efficacy. Improved OS was observed in the subgroups of advanced HCC patients including PD-L1-positive immune cell expression Sun et al. (2018). The gene discussed is CD274; the disease is hepatocellular carcinoma.